US FDA consults drug companies on best approaches to REMS assessment
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is seeking to improve how pharmaceutical companies assess whether their approved risk evaluation and mitigation strategy (REMS) for a marketed drug is achieving its intended goal of informing and educating patients and healthcare providers about the risks of the drug1.